Key result
Vitamin D supplementation (calcitriol and 25-hydroxyvitamin D3) is being evaluated for its impact on vascular stiffness in patients with chronic kidney disease in this study protocol, which reports no clinical results.
Why the study?
Does vitamin D supplementation (25-hydroxyvitamin D3 or calcitriol) reduce vascular stiffness in stable chronic kidney disease patients?
RCT (n=128)
Double-blind
1:1:1
Yes
Does vitamin D supplementation (25-hydroxyvitamin D3 or calcitriol) reduce vascular stiffness in stable chronic kidney disease patients?
This study protocol describes a randomized controlled trial designed to evaluate the mechanistic impact of different vitamin D formulations on vascular stiffness in patients with chronic kidney disease.
Answers are grounded in this paper and cite their sources.
No support for vitamin D supplementation to reduce CV events in CKD; reinforces null results from prior RCTs.
BACKGROUND: Vitamin D deficiency is associated with cardiovascular (CV) risk in multiple populations, including those with chronic kidney disease (CKD). The active form of the hormone (1,25 OH2D3) binds to receptors in multiple organs. CKD patients are deficient in both 25 Vitamin D and 1,25 OH2D3. Clinical trial data demonstrating the benefits of vitamin D formulations are limited, and fail to show significant benefits on CV outcomes, and have compared different compounds, in various populations, and focused on a variety of outcomes. A understanding of the mechanism by which different vitamin D compounds confer CV protection in CKD is important for the design of future studies. METHODS/DESIGN: This 3 arm randomized prospective double-blinded placebo-controlled study examining the impact of calcitriol (1,25 OH2D3) and 25-hydroxyvitamin D3 supplementation compared to placebo on vascular stiffness, as measured by pulse wave velocity (PWV). Patients are enrolled from 2 tertiary care institutions if they meet inclusion criteria (stable estimated glomerular filtration rate (eGFR) between 15-45ml/min, <±5ml/min change in previous 6 months), on stable doses of renin-angiotensin aldosterone system blockade. For those already receiving vitamin D therapies, a 3 month washout period before randomization is mandatory. Treatment duration is 6 months; medications are given thrice weekly in fixed doses. The primary outcome measure is Vascular stiffness, measured non-invasively by pulse wave velocity (PWV). Other measurements include BP, kidney function and serial blood levels of biomarkers. The primary analysis will compare any vitamin D therapy versus placebo for the primary outcome defined as the change of PWV from baseline to 6 months. Analysis of covariance will be used to detect differences between vitamin D preparations in the magnitude of reduction in PWV. DISCUSSION: This study is novel in that we are using a robust study design in CKD patients (not on dialysis) comparing placebo to different forms of vitamin D supplementation in fixed doses, irrespective of baseline values. We hope to demonstrate the biological mechanistic effect of vitamin D supplementation on vascular function in order for this information to be used in designing larger randomized controlled trials. TRIAL REGISTRATION: Current Controlled Trials NCT01247311. Date of Registration: November 12, 2010.
No takes yet. Share an insight, caveat, or question.
Levin et al. (2014) conducted an RCT in Chronic kidney disease (n=128). Vitamin D supplementation (calcitriol and 25-hydroxyvitamin D3) vs. Placebo was evaluated on Change in vascular stiffness, measured by pulse wave velocity (PWV), from baseline to 6 months. Vitamin D supplementation (calcitriol and 25-hydroxyvitamin D3) is being evaluated for its impact on vascular stiffness in patients with chronic kidney disease in this study protocol, which reports no clinical results.
Synapse has enriched 10 related papers. Consider them for comparative context: